search
Back to results

Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

Primary Purpose

Radiation Dermatitis

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
RadiaPlexRx Gel
Aquaphor Gel
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radiation Dermatitis focused on measuring Breast Cancer, Radiation Dermatitis, RadiaPlexRx Gel, Aquaphor

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient has histologically-confirmed carcinoma of breast (all subtypes are permitted)
  2. Patient has breast conserving surgery (lumpectomy) for breast cancer with negative surgical margin
  3. Stage Tis,0-3 N0-2 M0
  4. Patient will receive irradiation of whole breast. An additional field to treat the supraclavicular / axillary apex lymphatics is allowed, but a separate field to treat the internal mammary chain nodes is not allowed
  5. The breast will receive radiation dose greater than or equal to 50 Gy, with or without a boost field to give additional dose to the tumor bed
  6. Patient wears bras with cup size larger than A
  7. Patient signs informed consent

Exclusion Criteria:

  1. Breast cancer treatment with mastectomy
  2. Stage T4 breast cancer
  3. Patient will require the use of tissue-equivalent bolus during radiation treatment or double treatment of junctions of radiation treatment fields
  4. Patient will require treatment to the internal mammary chain lymph node bed using a separate radiation electron field
  5. Patient is planned for partial-breast irradiation or Mammo-site treatment.
  6. Patient has unhealed wound or rash in the radiation field
  7. Patient has allergy to RadiaPlexRx or aloe vera
  8. Patient has systemic lupus erythematosus or scleroderma that increases the risk of radiation dermatitis development
  9. Patient will receive concurrent chemotherapy with radiation. (Patient is allowed to take concurrent hormonal therapy or Herceptin® [Trastuzumab])
  10. Planned accelerated fractionation.
  11. Planned radiation therapy to the bilateral breasts
  12. Planned breast irradiation in the prone position

Sites / Locations

  • UT MD Anderson Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

RadiaPlexRx Gel

Aquaphor Gel

Arm Description

RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.

Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.

Outcomes

Primary Outcome Measures

Number of Patients using RadiaPlexRx Hydrogel that developed grade 2 or higher radiation dermatitis in breast cancer from adjuvant radiation compared to a petroleum-based gel (Aquaphor) commonly used as best supportive care

Secondary Outcome Measures

Full Information

First Posted
May 31, 2007
Last Updated
April 29, 2016
Sponsor
M.D. Anderson Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00481884
Brief Title
Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients
Official Title
Phase III Trial to Compare RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
January 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Primary Objective: To determine if RadiaPlexRx Hydrogel can reduce the development of grade 2 or higher radiation dermatitis in breast cancer from adjuvant radiation when compared to a petroleum-based gel (Aquaphor) commonly used as best supportive care.
Detailed Description
The Study Gels: RadiaPlexRx (requires a prescription) and Aquaphor (over-the-counter) are both gels that are designed to treat irradiated (received radiation) breast skin. These 2 gels contain different ingredients that may make one gel better than the other to treat irradiated breast skin. RadiaPlexRx contains hyaluronic acid (an ingredient found naturally in skin), aloe vera, and other ingredients that help the skin heal. Aquaphor is made of mostly petroleum that helps protect the skin. Application of Study Gels: If you decide to participate in this study, the following steps will be taken: You will be given detailed instructions on how to apply both of the gels. You should not apply other gels or lotions on the areas of skin where you will be instructed to apply the study gels, unless you are instructed to do so by the treating doctor. You will receive a supply of both gels (in tubes) with enough to last for the length of your treatment. You will know which gel is which, but each gel will be labeled with "outer" or "inner" so that you will know which gel to use on which side. You should not tell your treating doctor which side of the breast skin is being treated with which gel so that a fair comparison of the gels can be made. You will apply 1 gel to the outer side of the irradiated breast skin and the other gel to the inner side of the irradiated breast skin. If you experience any kind of allergic reaction (such as a rash) to the study gels, you should notify the study doctor or study staff immediately. Schedule for Study Gels: You will need to follow the schedule for applying the gels as follows: You will need to apply both gels starting 1 day before the start of radiation treatments. You will then need to apply both gels for 6 weeks during radiation treatment. During the study period (1 day before the start of radiation treatment, during 6 weeks of radiation treatment), you will need to apply both gels 3 times (in the morning, afternoon, and evening just before going to sleep) each day at home. During the days that you receive radiation treatment, you will be asked to apply the gels immediately after you receive your radiation treatment. This will count as 1 of the 3 daily gel applications. Clinic Visits: You will have the following tests done during your clinic visits: Three (3) sets of photos of your breast skin will be taken (before radiation starts and during Weeks 3 and 6 of radiation therapy treatment). During Weeks 1 through 6, you will go to the clinic to have your skin checked by your treating physician to learn the effects of each gel on your symptoms. . You will need to return any empty tubes of study gel so that new tubes can be given if you will need more. Length of Study: If the treating doctor sees that the irradiated breast skin reacts poorly (does not improve or gets worse) or you experience any intolerable side effects, you will be taken off this study. Otherwise, the total time on this study is about 6 weeks. End-of-Study: -During your last week of radiation therapy treatment you will be asked to fill out a questionnaire about how you felt about each gel. This is an investigational study. RadiaPlexRx and Aquaphor are both FDA approved and commercially available. Up to 92 patients will take part in this study. All will be enrolled at M. D. Anderson.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radiation Dermatitis
Keywords
Breast Cancer, Radiation Dermatitis, RadiaPlexRx Gel, Aquaphor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RadiaPlexRx Gel
Arm Type
Experimental
Arm Description
RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
Arm Title
Aquaphor Gel
Arm Type
Active Comparator
Arm Description
Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
Intervention Type
Other
Intervention Name(s)
RadiaPlexRx Gel
Intervention Description
RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
Intervention Type
Other
Intervention Name(s)
Aquaphor Gel
Intervention Description
Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
Primary Outcome Measure Information:
Title
Number of Patients using RadiaPlexRx Hydrogel that developed grade 2 or higher radiation dermatitis in breast cancer from adjuvant radiation compared to a petroleum-based gel (Aquaphor) commonly used as best supportive care
Time Frame
6 weeks

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient has histologically-confirmed carcinoma of breast (all subtypes are permitted) Patient has breast conserving surgery (lumpectomy) for breast cancer with negative surgical margin Stage Tis,0-3 N0-2 M0 Patient will receive irradiation of whole breast. An additional field to treat the supraclavicular / axillary apex lymphatics is allowed, but a separate field to treat the internal mammary chain nodes is not allowed The breast will receive radiation dose greater than or equal to 50 Gy, with or without a boost field to give additional dose to the tumor bed Patient wears bras with cup size larger than A Patient signs informed consent Exclusion Criteria: Breast cancer treatment with mastectomy Stage T4 breast cancer Patient will require the use of tissue-equivalent bolus during radiation treatment or double treatment of junctions of radiation treatment fields Patient will require treatment to the internal mammary chain lymph node bed using a separate radiation electron field Patient is planned for partial-breast irradiation or Mammo-site treatment. Patient has unhealed wound or rash in the radiation field Patient has allergy to RadiaPlexRx or aloe vera Patient has systemic lupus erythematosus or scleroderma that increases the risk of radiation dermatitis development Patient will receive concurrent chemotherapy with radiation. (Patient is allowed to take concurrent hormonal therapy or Herceptin® [Trastuzumab]) Planned accelerated fractionation. Planned radiation therapy to the bilateral breasts Planned breast irradiation in the prone position
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Buchholz, MD
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
UT MD Anderson Cancer Center website

Learn more about this trial

Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

We'll reach out to this number within 24 hrs